This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Kizfizo, temozolomide,...
Human medicines European public assessment report (EPAR): Deqsiga, human normal ...
Four new medicines recommended for approvalEMA’s human medicines committee (CHMP...
The Department of Health and Human Services is reevaluating a $590 million contr...
AbbVie-partnered Mission Therapeutics is tweaking its trajectory, closing a prec...
Mental health treatments face higher regulatory hurdles for approval, warns Impe...
The molecular glue wave that first began years ago is still swelling, with Eli L...
Despite falling business interest in environmental, social and governance polici...
Nxera Pharma has sold the Asia-Pacific rights to its phase 3 autoimmune drug to ...
List of centrally authorised products with safety-related changes to the product...
Procedural advice on CHMP/CAT/PRAC Rapporteur/Co-Rapporteur appointment principl...
Human medicines European public assessment report (EPAR): Fluenz, influenza vacc...
“With the right policies, advanced science, and strong leadership in government ...
I tested out Grok, my company’s diagnostic AI, and several others to see which w...
Clinical investigation of medicinal products in the treatment of patients with a...
Draft guideline on the clinical investigation of medicinal products in the treat...
Despite falling business interest in environmental, social and governance polici...
THURSDAY, Feb. 27, 2025 -- Adults with autism have high rates of co-occurring a...
Pfizer made changes to its DEI webpage, joining other companies across different...
On Monday, Delaware’s state investment board approved a $30.2 million grant to M...